Advertisement · 728 × 90

Posts by Zacks Small Cap Research

Post image

$COSM Launches US Products with Huge Market Potential buff.ly/sfP7Ddz

22 hours ago 0 0 0 0
Post image

$TRX Advances Toward Larger Scale, Higher Margin Production buff.ly/oJf8f5N

1 day ago 0 0 0 0
Post image

$SBC: View Secondary Offering as a Positive For Share Trading Liquidity buff.ly/YkEc0JC

1 day ago 0 0 0 0
Post image

$AINMF: Expanding Number of Agreements, Cash Runway Extended buff.ly/qMnnYSS

2 days ago 0 0 0 0
Post image

$MKTW: Focus on Quality over Quantity. Initiating coverage of a financial market content leader. buff.ly/DC6OZDx

2 days ago 0 0 0 0
Post image

$RVPH: Shareholder Letter Introduces New IP buff.ly/RYI1Dge

3 days ago 0 0 0 0
Post image

$CCLD: Adjusting Estimates to Reflect the Preferred Redemption and Seasonality in Health Care Usage buff.ly/Ws02jmR

3 days ago 0 0 0 0
Initiating Coverage of Rapid-Growing PRE By Brad Sorensen, CFA NASDAQ: PRE READ THE FULL PRE RESEARCH REPORT Zacks SCR is initiating coverage of Prenetics Global Limited (NASDAQ: PRE). Prenetics is a health care company focused on the premiu...

Read the full initiation report: scr.zacks.com/news/news-de...

5 days ago 0 0 0 0
Advertisement
Prenetics Global (PRE) | 480% Revenue Growth & $120M ARR in 12 Months | Zacks SCR Initiates Coverage
Prenetics Global (PRE) | 480% Revenue Growth & $120M ARR in 12 Months | Zacks SCR Initiates Coverage YouTube video by Zacks Investment Awareness

$PRE initiated at $30 price target from Zacks SCR. IM8 brand hit $120M ARR in 12 months. Company debt-free with $170M cash. Athlete partnerships structured as equity, not endorsement fees.

youtu.be/IIfurXL7wtc

5 days ago 0 0 1 0
Post image

$NRXBF Worth a Look at This Stage buff.ly/WvIDJeN

5 days ago 0 0 0 0
Post image

$HCTI Releases Earnings and Shows Great Improvement buff.ly/u2V8guB

6 days ago 0 0 0 0
Post image

$COSM Earnings Show Rapid Revenue Growth buff.ly/gKnXjmw

6 days ago 1 0 0 0
Post image

$QNRX: Preparing to Commercialize Lead Asset Through Global Sales Infrastructure buff.ly/1wZjIXL

1 week ago 0 0 0 0
Post image

$HOVR: Remains focused on the big picture. Still expecting a complete, full-scale prototype in 2026. buff.ly/c33dc2l

1 week ago 0 0 0 0
KBSX: Initiation of Fast Growing Global Manufacturer and Distributor of Steel and Graphite Golf Shafts

Full report: scr.zacks.com/news/news-de...

1 week ago 0 0 0 0
From OEM to Global Brand: Zacks SCR Initiates on FST Corp. (KBSX)
From OEM to Global Brand: Zacks SCR Initiates on FST Corp. (KBSX) YouTube video by Zacks Investment Awareness

$KBSX (FST Corp.): ~$57M market cap, ~$48M revenue, targeting profitability in 2026, $3.00 price target. Worth a look. #KBSX #smallcap #microcap

youtu.be/GQlpnZ9dVrI

1 week ago 0 0 1 0
Advertisement
Post image

$CLPMF Clip Money Reports 143% Revenue Growth For 2025 buff.ly/jv4pOmc

1 week ago 0 0 0 0
Preview
DYLLF: Flagship Tumas Project Continues to be Developed by Pre-Production Work Streams; Price Sensitivity Analysis of Tumas Project; Updates on Mulga Rock & Alligator River Projects; Commentary on Rec... By Steven Ralston, CFA OTCQX: DYLLF | ASX: DYL READ THE FULL DYLLF RESEARCH REPORT SUMMARY OF RECENT EVENTS Continuing Development of flagship Tumas Project Greg Field Assumed role of CEO on February ...

$DYLLF $DYL: Flagship Tumas Project Continues to be Developed by Pre-Production Work Streams; Price Sensitivity Analysis of Tumas Project; Updates on Mulga Rock & Alligator River Projects; Commentary on Recent Price Action of Uranium buff.ly/wtHDbNt

1 week ago 0 0 0 0
Post image

$LOT: Margin gains due to strong service revenue highlight Q4 performance. 2026 still poised to be turnaround year for Lotus despite a challenging economic backdrop. buff.ly/Yevlzyg

1 week ago 0 0 0 0
Post image

$IZOZF Makes Good Progress Toward Revenue Generation buff.ly/cvmNMHB

1 week ago 0 0 0 0

Read the full report: scr.zacks.com/news/news-de...

1 week ago 0 0 0 0
RenX Enterprises ($RENX): FY2025 Revenue Beats Guidance | Zacks SCR Update
RenX Enterprises ($RENX): FY2025 Revenue Beats Guidance | Zacks SCR Update YouTube video by Zacks Investment Awareness

$RENX is building a high-margin compost operation alongside a stable logistics business anchored by long-term municipal contracts. Q4 compost margins reached 57%, and new equipment is on the way. Still working toward profitability. #RENX #smallcap #growthinvesting #sustainability #wastemanagement

1 week ago 1 0 1 0
Post image

$HURA: 2025 Financial Results buff.ly/iNWanoC

1 week ago 0 0 0 0
Post image

$COSM Announces Liver Health Product with Large Upside Potential buff.ly/1jdWYvb

1 week ago 0 0 0 0
Post image

$AMS: Benefits of O&O Strategy Obscured by Lease Expirations, Equipment Upgrades buff.ly/uaOZjR0

2 weeks ago 0 0 0 0
Post image

$CVKD: Results Show 12-LOX Inhibition Targets Inflammation from Obesity and Type 2 Diabetes buff.ly/hkIYTpj

2 weeks ago 0 0 0 0
Advertisement
Post image

Initiating Coverage of Rapid-Growing $PRE buff.ly/216Ezbz

2 weeks ago 0 0 0 0
Post image

$COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention buff.ly/oRdyhJV

2 weeks ago 0 0 0 0
BDRX: Initiating Coverage of Biodexa Pharmaceuticals; A Deep Value Oncology Platform Built Around Two High-Conviction Areas

Full report: scr.zacks.com/news/news-de...

2 weeks ago 0 0 0 0
BDRX | Zacks SCR Initiates Coverage of Biodexa Pharmaceuticals with $7.00 Valuation
BDRX | Zacks SCR Initiates Coverage of Biodexa Pharmaceuticals with $7.00 Valuation YouTube video by Zacks Investment Awareness

New Coverage: $BDRX. Clinical-stage GI oncology platform with a first-in-class GIST program and a registrational Phase 3 trial for FAP. Zacks SCR initiates at $7.00. Watch: youtu.be/QpfenwqQi8k #biotech #raredisease #smallcap

2 weeks ago 1 0 1 0